FDA accepts Zalviso NDA; AcelRx rises
This article was originally published in Scrip
Executive Summary
Shares of AcelRx Pharmaceuticals got a 3.8% boost on 2 December on word the US FDA had accepted for review the new drug application (NDA) for Zalviso as a treatment for moderate-to-severe acute pain in the hospital setting.